APO Research
Talk to an analyst

APO RESEARCH · REPORT

Choroidal Neovascularization Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Choroidal Neovascularization Drug Market Analysis and Forecast 2026-2032

19 December 2025208 pages

Choose your research edition.

Industry ResearchChoroidal Neovascularization Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Choroidal Neovascularization Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Choroidal Neovascularization Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Choroidal Neovascularization Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Choroidal Neovascularization Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Choroidal Neovascularization Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Choroidal Neovascularization Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Choroidal Neovascularization Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Choroidal Neovascularization Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Choroidal Neovascularization Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Choroidal Neovascularization Drug include Eli Lilly and Company, Soligenix, Inc., RxBio, Inc., RedHill Biopharma Ltd., RDD Pharma Ltd., ProCertus BioPharm Inc., Pluristem Therapeutics Inc., PharmaIN Corporation and Onconova Therapeutics, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Choroidal Neovascularization Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Choroidal Neovascularization Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Choroidal Neovascularization Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Choroidal Neovascularization Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Choroidal Neovascularization Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Choroidal Neovascularization Drug sales, projected growth trends, production technology, application and end-user industry.

Choroidal Neovascularization Drug Segment by Company

Eli Lilly and Company

Soligenix, Inc.

RxBio, Inc.

RedHill Biopharma Ltd.

RDD Pharma Ltd.

ProCertus BioPharm Inc.

Pluristem Therapeutics Inc.

PharmaIN Corporation

Onconova Therapeutics, Inc.

Neumedicines Inc.

Meabco A/S

INSYS Therapeutics, Inc.

Humanetics Corporation

GNI Group Ltd.

Diffusion Pharmaceuticals Inc.

Cumberland Pharmaceuticals, Inc.

Cleveland BioLabs, Inc.

Chrysalis BioTherapeutics, Inc.

Cellphire, Inc.

Choroidal Neovascularization Drug Segment by Type

EWA-001

Entolimod

DG-3

BBT-007

BB-3

AVMOC-001

Others

Choroidal Neovascularization Drug Segment by Application

Clinic

Hospital

Others

Choroidal Neovascularization Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Choroidal Neovascularization Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Choroidal Neovascularization Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Choroidal Neovascularization Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Choroidal Neovascularization Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Choroidal Neovascularization Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Choroidal Neovascularization Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Choroidal Neovascularization Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. EWA-001 Major Manufacturers Table 3. Entolimod Major Manufacturers Table 4. DG-3 Major Manufacturers Table 5. BBT-007 Major Manufacturers Table 6. BB-3 Major Manufacturers Table 7. AVMOC-001 Major Manufacturers Table 8. Others Major Manufacturers Table 9. Global Choroidal Neovascularization Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Clinic Major Manufacturers Table 11. Hospital Major Manufacturers Table 12. Others Major Manufacturers Table 13. Choroidal Neovascularization Drug Industry Trends Table 14. Choroidal Neovascularization Drug Industry Drivers Table 15. Choroidal Neovascularization Drug Industry Opportunities and Challenges Table 16. Choroidal Neovascularization Drug Industry Restraints Table 17. Global Choroidal Neovascularization Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Choroidal Neovascularization Drug Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Choroidal Neovascularization Drug Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2021-2026) Table 21. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2027-2032) Table 22. Global Choroidal Neovascularization Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 23. Global Choroidal Neovascularization Drug Sales by Region (2021-2026) & (K Units) Table 24. Global Choroidal Neovascularization Drug Sales by Region (2027-2032) & (K Units) Table 25. Global Choroidal Neovascularization Drug Sales Market Share by Region (2021-2026) Table 26. Global Choroidal Neovascularization Drug Sales Market Share by Region (2027-2032) Table 27. Global Choroidal Neovascularization Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Choroidal Neovascularization Drug Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Choroidal Neovascularization Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Choroidal Neovascularization Drug Sales Market Share by Manufacturers (2021-2026) Table 31. Global Choroidal Neovascularization Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 32. Global Choroidal Neovascularization Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Choroidal Neovascularization Drug Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Choroidal Neovascularization Drug Manufacturers, Product Type & Application Table 35. Global Choroidal Neovascularization Drug Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Choroidal Neovascularization Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Choroidal Neovascularization Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Choroidal Neovascularization Drug Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Choroidal Neovascularization Drug Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2021-2026) Table 42. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2027-2032) Table 43. Global Choroidal Neovascularization Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 44. Global Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 45. Global Choroidal Neovascularization Drug Sales by Type (2027-2032) & (K Units) Table 46. Global Choroidal Neovascularization Drug Sales Market Share by Type (2021-2026) Table 47. Global Choroidal Neovascularization Drug Sales Market Share by Type (2027-2032) Table 48. Global Choroidal Neovascularization Drug Price by Type (2021-2026) & (US$/Unit) Table 49. Global Choroidal Neovascularization Drug Price by Type (2027-2032) & (US$/Unit) Table 50. Global Choroidal Neovascularization Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Choroidal Neovascularization Drug Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Choroidal Neovascularization Drug Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2021-2026) Table 54. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2027-2032) Table 55. Global Choroidal Neovascularization Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 56. Global Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 57. Global Choroidal Neovascularization Drug Sales by Application (2027-2032) & (K Units) Table 58. Global Choroidal Neovascularization Drug Sales Market Share by Application (2021-2026) Table 59. Global Choroidal Neovascularization Drug Sales Market Share by Application (2027-2032) Table 60. Global Choroidal Neovascularization Drug Price by Application (2021-2026) & (US$/Unit) Table 61. Global Choroidal Neovascularization Drug Price by Application (2027-2032) & (US$/Unit) Table 62. Eli Lilly and Company Company Information Table 63. Eli Lilly and Company Business Overview Table 64. Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio Table 66. Eli Lilly and Company Recent Development Table 67. Soligenix, Inc. Company Information Table 68. Soligenix, Inc. Business Overview Table 69. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio Table 71. Soligenix, Inc. Recent Development Table 72. RxBio, Inc. Company Information Table 73. RxBio, Inc. Business Overview Table 74. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio Table 76. RxBio, Inc. Recent Development Table 77. RedHill Biopharma Ltd. Company Information Table 78. RedHill Biopharma Ltd. Business Overview Table 79. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio Table 81. RedHill Biopharma Ltd. Recent Development Table 82. RDD Pharma Ltd. Company Information Table 83. RDD Pharma Ltd. Business Overview Table 84. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio Table 86. RDD Pharma Ltd. Recent Development Table 87. ProCertus BioPharm Inc. Company Information Table 88. ProCertus BioPharm Inc. Business Overview Table 89. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio Table 91. ProCertus BioPharm Inc. Recent Development Table 92. Pluristem Therapeutics Inc. Company Information Table 93. Pluristem Therapeutics Inc. Business Overview Table 94. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio Table 96. Pluristem Therapeutics Inc. Recent Development Table 97. PharmaIN Corporation Company Information Table 98. PharmaIN Corporation Business Overview Table 99. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio Table 101. PharmaIN Corporation Recent Development Table 102. Onconova Therapeutics, Inc. Company Information Table 103. Onconova Therapeutics, Inc. Business Overview Table 104. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 106. Onconova Therapeutics, Inc. Recent Development Table 107. Neumedicines Inc. Company Information Table 108. Neumedicines Inc. Business Overview Table 109. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio Table 111. Neumedicines Inc. Recent Development Table 112. Meabco A/S Company Information Table 113. Meabco A/S Business Overview Table 114. Meabco A/S Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Meabco A/S Choroidal Neovascularization Drug Product Portfolio Table 116. Meabco A/S Recent Development Table 117. INSYS Therapeutics, Inc. Company Information Table 118. INSYS Therapeutics, Inc. Business Overview Table 119. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 121. INSYS Therapeutics, Inc. Recent Development Table 122. Humanetics Corporation Company Information Table 123. Humanetics Corporation Business Overview Table 124. Humanetics Corporation Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio Table 126. Humanetics Corporation Recent Development Table 127. GNI Group Ltd. Company Information Table 128. GNI Group Ltd. Business Overview Table 129. GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio Table 131. GNI Group Ltd. Recent Development Table 132. Diffusion Pharmaceuticals Inc. Company Information Table 133. Diffusion Pharmaceuticals Inc. Business Overview Table 134. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio Table 136. Diffusion Pharmaceuticals Inc. Recent Development Table 137. Cumberland Pharmaceuticals, Inc. Company Information Table 138. Cumberland Pharmaceuticals, Inc. Business Overview Table 139. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio Table 141. Cumberland Pharmaceuticals, Inc. Recent Development Table 142. Cleveland BioLabs, Inc. Company Information Table 143. Cleveland BioLabs, Inc. Business Overview Table 144. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio Table 146. Cleveland BioLabs, Inc. Recent Development Table 147. Chrysalis BioTherapeutics, Inc. Company Information Table 148. Chrysalis BioTherapeutics, Inc. Business Overview Table 149. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 151. Chrysalis BioTherapeutics, Inc. Recent Development Table 152. Cellphire, Inc. Company Information Table 153. Cellphire, Inc. Business Overview Table 154. Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio Table 156. Cellphire, Inc. Recent Development Table 157. North America Choroidal Neovascularization Drug Revenue by Type (2021-2026) & (US$ Million) Table 158. North America Choroidal Neovascularization Drug Revenue by Type (2027-2032) & (US$ Million) Table 159. North America Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 160. North America Choroidal Neovascularization Drug Sales by Type (2027-2032) & (K Units) Table 161. North America Choroidal Neovascularization Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 162. North America Choroidal Neovascularization Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 163. North America Choroidal Neovascularization Drug Revenue by Application (2021-2026) & (US$ Million) Table 164. North America Choroidal Neovascularization Drug Revenue by Application (2027-2032) & (US$ Million) Table 165. North America Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 166. North America Choroidal Neovascularization Drug Sales by Application (2027-2032) & (K Units) Table 167. North America Choroidal Neovascularization Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 168. North America Choroidal Neovascularization Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 169. North America Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. North America Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 171. North America Choroidal Neovascularization Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 172. North America Choroidal Neovascularization Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 173. North America Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 174. North America Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 175. North America Choroidal Neovascularization Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 176. North America Choroidal Neovascularization Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 177. United States Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 178. Canada Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 179. Europe Choroidal Neovascularization Drug Revenue by Type (2021-2026) & (US$ Million) Table 180. Europe Choroidal Neovascularization Drug Revenue by Type (2027-2032) & (US$ Million) Table 181. Europe Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 182. Europe Choroidal Neovascularization Drug Sales by Type (2027-2032) & (K Units) Table 183. Europe Choroidal Neovascularization Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 184. Europe Choroidal Neovascularization Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 185. Europe Choroidal Neovascularization Drug Revenue by Application (2021-2026) & (US$ Million) Table 186. Europe Choroidal Neovascularization Drug Revenue by Application (2027-2032) & (US$ Million) Table 187. Europe Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 188. Europe Choroidal Neovascularization Drug Sales by Application (2027-2032) & (K Units) Table 189. Europe Choroidal Neovascularization Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 190. Europe Choroidal Neovascularization Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 191. Europe Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 192. Europe Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 193. Europe Choroidal Neovascularization Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 194. Europe Choroidal Neovascularization Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 195. Europe Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 196. Europe Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 197. Europe Choroidal Neovascularization Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 198. Europe Choroidal Neovascularization Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 199. Germany Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 200. France Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 201. U.K. Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 202. Italy Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 203. Netherlands Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 204. China Choroidal Neovascularization Drug Revenue by Type (2021-2026) & (US$ Million) Table 205. China Choroidal Neovascularization Drug Revenue by Type (2027-2032) & (US$ Million) Table 206. China Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 207. China Choroidal Neovascularization Drug Sales by Type (2027-2032) & (K Units) Table 208. China Choroidal Neovascularization Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 209. China Choroidal Neovascularization Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 210. China Choroidal Neovascularization Drug Revenue by Application (2021-2026) & (US$ Million) Table 211. China Choroidal Neovascularization Drug Revenue by Application (2027-2032) & (US$ Million) Table 212. China Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 213. China Choroidal Neovascularization Drug Sales by Application (2027-2032) & (K Units) Table 214. China Choroidal Neovascularization Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 215. China Choroidal Neovascularization Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 216. Asia Choroidal Neovascularization Drug Revenue by Type (2021-2026) & (US$ Million) Table 217. Asia Choroidal Neovascularization Drug Revenue by Type (2027-2032) & (US$ Million) Table 218. Asia Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 219. Asia Choroidal Neovascularization Drug Sales by Type (2027-2032) & (K Units) Table 220. Asia Choroidal Neovascularization Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 221. Asia Choroidal Neovascularization Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 222. Asia Choroidal Neovascularization Drug Revenue by Application (2021-2026) & (US$ Million) Table 223. Asia Choroidal Neovascularization Drug Revenue by Application (2027-2032) & (US$ Million) Table 224. Asia Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 225. Asia Choroidal Neovascularization Drug Sales by Application (2027-2032) & (K Units) Table 226. Asia Choroidal Neovascularization Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 227. Asia Choroidal Neovascularization Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 228. Asia Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 229. Asia Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 230. Asia Choroidal Neovascularization Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 231. Asia Choroidal Neovascularization Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 232. Asia Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 233. Asia Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 234. Asia Choroidal Neovascularization Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 235. Asia Choroidal Neovascularization Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 236. Japan Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 237. South Korea Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 238. India Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 239. Australia Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 240. China Taiwan Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 241. Southeast Asia Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 242. SAMEA Choroidal Neovascularization Drug Revenue by Type (2021-2026) & (US$ Million) Table 243. SAMEA Choroidal Neovascularization Drug Revenue by Type (2027-2032) & (US$ Million) Table 244. SAMEA Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 245. SAMEA Choroidal Neovascularization Drug Sales by Type (2027-2032) & (K Units) Table 246. SAMEA Choroidal Neovascularization Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 247. SAMEA Choroidal Neovascularization Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 248. SAMEA Choroidal Neovascularization Drug Revenue by Application (2021-2026) & (US$ Million) Table 249. SAMEA Choroidal Neovascularization Drug Revenue by Application (2027-2032) & (US$ Million) Table 250. SAMEA Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 251. SAMEA Choroidal Neovascularization Drug Sales by Application (2027-2032) & (K Units) Table 252. SAMEA Choroidal Neovascularization Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 253. SAMEA Choroidal Neovascularization Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 254. SAMEA Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 255. SAMEA Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 256. SAMEA Choroidal Neovascularization Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 257. SAMEA Choroidal Neovascularization Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 258. SAMEA Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 259. SAMEA Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 260. SAMEA Choroidal Neovascularization Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 261. SAMEA Choroidal Neovascularization Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 262. Brazil Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 263. Argentina Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 264. Chile Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 265. Colombia Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 266. Peru Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 267. Saudi Arabia Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 268. Israel Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 269. UAE Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 270. Turkey Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 271. Iran Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 272. Egypt Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Table 273. Key Raw Materials Table 274. Raw Materials Key Suppliers Table 275. Choroidal Neovascularization Drug Distributors List Table 276. Choroidal Neovascularization Drug Customers List Table 277. Research Programs/Design for This Report Table 278. Authors List of This Report Table 279. Secondary Sources Table 280. Primary Sources List of Figures Figure 1. Choroidal Neovascularization Drug Image Figure 2. Global Choroidal Neovascularization Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Choroidal Neovascularization Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. EWA-001 Image Figure 5. Entolimod Image Figure 6. DG-3 Image Figure 7. BBT-007 Image Figure 8. BB-3 Image Figure 9. AVMOC-001 Image Figure 10. Others Image Figure 11. Global Choroidal Neovascularization Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Choroidal Neovascularization Drug Market Size Share 2021 VS 2025 VS 2032 Figure 13. Clinic Image Figure 14. Hospital Image Figure 15. Others Image Figure 16. Global Choroidal Neovascularization Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Figure 18. Global Choroidal Neovascularization Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Choroidal Neovascularization Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2021-2032) Figure 21. Global Choroidal Neovascularization Drug Sales (2021-2032) & (K Units) Figure 22. Global Choroidal Neovascularization Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 23. Global Choroidal Neovascularization Drug Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Choroidal Neovascularization Drug Sales YoY (2021-2032) & (K Units) Figure 25. Europe Choroidal Neovascularization Drug Sales YoY (2021-2032) & (K Units) Figure 26. China Choroidal Neovascularization Drug Sales YoY (2021-2032) & (K Units) Figure 27. Asia (Excluding China) Choroidal Neovascularization Drug Sales YoY (2021-2032) & (K Units) Figure 28. South America, Middle East and Africa Choroidal Neovascularization Drug Sales YoY (2021-2032) & (K Units) Figure 29. Global Choroidal Neovascularization Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Choroidal Neovascularization Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Choroidal Neovascularization Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Choroidal Neovascularization Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2021-2032) Figure 35. Global Choroidal Neovascularization Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Choroidal Neovascularization Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Choroidal Neovascularization Drug Sales Market Share by Type (2021-2032) Figure 38. Global Choroidal Neovascularization Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Choroidal Neovascularization Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2021-2032) Figure 41. Global Choroidal Neovascularization Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 42. Global Choroidal Neovascularization Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Choroidal Neovascularization Drug Sales Market Share by Application (2021-2032) Figure 44. North America Choroidal Neovascularization Drug Revenue Share by Type (2021-2032) Figure 45. North America Choroidal Neovascularization Drug Sales Share by Type (2021-2032) Figure 46. North America Choroidal Neovascularization Drug Revenue Share by Application (2021-2032) Figure 47. North America Choroidal Neovascularization Drug Sales Share by Application (2021-2032) Figure 48. North America Choroidal Neovascularization Drug Revenue Share by Country (2021-2032) Figure 49. North America Choroidal Neovascularization Drug Sales Share by Country (2021-2032) Figure 50. Europe Choroidal Neovascularization Drug Revenue Share by Type (2021-2032) Figure 51. Europe Choroidal Neovascularization Drug Sales Share by Type (2021-2032) Figure 52. Europe Choroidal Neovascularization Drug Revenue Share by Application (2021-2032) Figure 53. Europe Choroidal Neovascularization Drug Sales Share by Application (2021-2032) Figure 54. Europe Choroidal Neovascularization Drug Revenue Share by Country (2021-2032) Figure 55. Europe Choroidal Neovascularization Drug Sales Share by Country (2021-2032) Figure 56. China Choroidal Neovascularization Drug Revenue Share by Type (2021-2032) Figure 57. China Choroidal Neovascularization Drug Sales Share by Type (2021-2032) Figure 58. China Choroidal Neovascularization Drug Revenue Share by Application (2021-2032) Figure 59. China Choroidal Neovascularization Drug Sales Share by Application (2021-2032) Figure 60. Asia Choroidal Neovascularization Drug Revenue Share by Type (2021-2032) Figure 61. Asia Choroidal Neovascularization Drug Sales Share by Type (2021-2032) Figure 62. Asia Choroidal Neovascularization Drug Revenue Share by Application (2021-2032) Figure 63. Asia Choroidal Neovascularization Drug Sales Share by Application (2021-2032) Figure 64. Asia Choroidal Neovascularization Drug Revenue Share by Country (2021-2032) Figure 65. Asia Choroidal Neovascularization Drug Sales Share by Country (2021-2032) Figure 66. SAMEA Choroidal Neovascularization Drug Revenue Share by Type (2021-2032) Figure 67. SAMEA Choroidal Neovascularization Drug Sales Share by Type (2021-2032) Figure 68. SAMEA Choroidal Neovascularization Drug Revenue Share by Application (2021-2032) Figure 69. SAMEA Choroidal Neovascularization Drug Sales Share by Application (2021-2032) Figure 70. SAMEA Choroidal Neovascularization Drug Revenue Share by Country (2021-2032) Figure 71. SAMEA Choroidal Neovascularization Drug Sales Share by Country (2021-2032) Figure 72. Choroidal Neovascularization Drug Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Choroidal Neovascularization Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • EWA-001
  • Entolimod
  • DG-3
  • BBT-007
  • BB-3
  • AVMOC-001
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Eli Lilly and Company
  • Soligenix, Inc.
  • RxBio, Inc.
  • RedHill Biopharma Ltd.
  • RDD Pharma Ltd.
  • ProCertus BioPharm Inc.
  • Pluristem Therapeutics Inc.
  • PharmaIN Corporation
  • Onconova Therapeutics, Inc.
  • Neumedicines Inc.
  • Meabco A/S
  • INSYS Therapeutics, Inc.
  • Humanetics Corporation
  • GNI Group Ltd.
  • Diffusion Pharmaceuticals Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Cleveland BioLabs, Inc.
  • Chrysalis BioTherapeutics, Inc.
  • Cellphire, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Choroidal Neovascularization Drug Market by Type
  3. 1.2.1 Global Choroidal Neovascularization Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 EWA-001
  5. 1.2.3 Entolimod
  6. 1.2.4 DG-3
  7. 1.2.5 BBT-007
  8. 1.2.6 BB-3
  9. 1.2.7 AVMOC-001
  10. 1.2.8 Others
  11. 1.3 Choroidal Neovascularization Drug Market by Application
  12. 1.3.1 Global Choroidal Neovascularization Drug Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Clinic
  14. 1.3.3 Hospital
  15. 1.3.4 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Choroidal Neovascularization Drug Market Dynamics
  1. 2.1 Choroidal Neovascularization Drug Industry Trends
  2. 2.2 Choroidal Neovascularization Drug Industry Drivers
  3. 2.3 Choroidal Neovascularization Drug Industry Opportunities and Challenges
  4. 2.4 Choroidal Neovascularization Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Choroidal Neovascularization Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Choroidal Neovascularization Drug Revenue by Region
  3. 3.2.1 Global Choroidal Neovascularization Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Choroidal Neovascularization Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Choroidal Neovascularization Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Choroidal Neovascularization Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Choroidal Neovascularization Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Choroidal Neovascularization Drug Sales by Region
  9. 3.4.1 Global Choroidal Neovascularization Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Choroidal Neovascularization Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Choroidal Neovascularization Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Choroidal Neovascularization Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Choroidal Neovascularization Drug Revenue by Manufacturers
  2. 4.1.1 Global Choroidal Neovascularization Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Choroidal Neovascularization Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Choroidal Neovascularization Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Choroidal Neovascularization Drug Sales by Manufacturers
  6. 4.2.1 Global Choroidal Neovascularization Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Choroidal Neovascularization Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Choroidal Neovascularization Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Choroidal Neovascularization Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Choroidal Neovascularization Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Choroidal Neovascularization Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Choroidal Neovascularization Drug Manufacturers, Product Type & Application
  13. 4.7 Global Choroidal Neovascularization Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Choroidal Neovascularization Drug Market CR5 and HHI
  16. 4.8.2 2025 Choroidal Neovascularization Drug Tier 1, Tier 2, and Tier 3
5 Choroidal Neovascularization Drug Market by Type
  1. 5.1 Global Choroidal Neovascularization Drug Revenue by Type
  2. 5.1.1 Global Choroidal Neovascularization Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Choroidal Neovascularization Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Choroidal Neovascularization Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Choroidal Neovascularization Drug Sales by Type
  6. 5.2.1 Global Choroidal Neovascularization Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Choroidal Neovascularization Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Choroidal Neovascularization Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Choroidal Neovascularization Drug Price by Type
6 Choroidal Neovascularization Drug Market by Application
  1. 6.1 Global Choroidal Neovascularization Drug Revenue by Application
  2. 6.1.1 Global Choroidal Neovascularization Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Choroidal Neovascularization Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Choroidal Neovascularization Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Choroidal Neovascularization Drug Sales by Application
  6. 6.2.1 Global Choroidal Neovascularization Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Choroidal Neovascularization Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Choroidal Neovascularization Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Choroidal Neovascularization Drug Price by Application
7 Company Profiles
  1. 7.1 Eli Lilly and Company
  2. 7.1.1 Eli Lilly and Company Company Information
  3. 7.1.2 Eli Lilly and Company Business Overview
  4. 7.1.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio
  6. 7.1.5 Eli Lilly and Company Recent Developments
  7. 7.2 Soligenix, Inc.
  8. 7.2.1 Soligenix, Inc. Company Information
  9. 7.2.2 Soligenix, Inc. Business Overview
  10. 7.2.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio
  12. 7.2.5 Soligenix, Inc. Recent Developments
  13. 7.3 RxBio, Inc.
  14. 7.3.1 RxBio, Inc. Company Information
  15. 7.3.2 RxBio, Inc. Business Overview
  16. 7.3.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio
  18. 7.3.5 RxBio, Inc. Recent Developments
  19. 7.4 RedHill Biopharma Ltd.
  20. 7.4.1 RedHill Biopharma Ltd. Company Information
  21. 7.4.2 RedHill Biopharma Ltd. Business Overview
  22. 7.4.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio
  24. 7.4.5 RedHill Biopharma Ltd. Recent Developments
  25. 7.5 RDD Pharma Ltd.
  26. 7.5.1 RDD Pharma Ltd. Company Information
  27. 7.5.2 RDD Pharma Ltd. Business Overview
  28. 7.5.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio
  30. 7.5.5 RDD Pharma Ltd. Recent Developments
  31. 7.6 ProCertus BioPharm Inc.
  32. 7.6.1 ProCertus BioPharm Inc. Company Information
  33. 7.6.2 ProCertus BioPharm Inc. Business Overview
  34. 7.6.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio
  36. 7.6.5 ProCertus BioPharm Inc. Recent Developments
  37. 7.7 Pluristem Therapeutics Inc.
  38. 7.7.1 Pluristem Therapeutics Inc. Company Information
  39. 7.7.2 Pluristem Therapeutics Inc. Business Overview
  40. 7.7.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio
  42. 7.7.5 Pluristem Therapeutics Inc. Recent Developments
  43. 7.8 PharmaIN Corporation
  44. 7.8.1 PharmaIN Corporation Company Information
  45. 7.8.2 PharmaIN Corporation Business Overview
  46. 7.8.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio
  48. 7.8.5 PharmaIN Corporation Recent Developments
  49. 7.9 Onconova Therapeutics, Inc.
  50. 7.9.1 Onconova Therapeutics, Inc. Company Information
  51. 7.9.2 Onconova Therapeutics, Inc. Business Overview
  52. 7.9.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  54. 7.9.5 Onconova Therapeutics, Inc. Recent Developments
  55. 7.10 Neumedicines Inc.
  56. 7.10.1 Neumedicines Inc. Company Information
  57. 7.10.2 Neumedicines Inc. Business Overview
  58. 7.10.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio
  60. 7.10.5 Neumedicines Inc. Recent Developments
  61. 7.11 Meabco A/S
  62. 7.11.1 Meabco A/S Company Information
  63. 7.11.2 Meabco A/S Business Overview
  64. 7.11.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Meabco A/S Choroidal Neovascularization Drug Product Portfolio
  66. 7.11.5 Meabco A/S Recent Developments
  67. 7.12 INSYS Therapeutics, Inc.
  68. 7.12.1 INSYS Therapeutics, Inc. Company Information
  69. 7.12.2 INSYS Therapeutics, Inc. Business Overview
  70. 7.12.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  72. 7.12.5 INSYS Therapeutics, Inc. Recent Developments
  73. 7.13 Humanetics Corporation
  74. 7.13.1 Humanetics Corporation Company Information
  75. 7.13.2 Humanetics Corporation Business Overview
  76. 7.13.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio
  78. 7.13.5 Humanetics Corporation Recent Developments
  79. 7.14 GNI Group Ltd.
  80. 7.14.1 GNI Group Ltd. Company Information
  81. 7.14.2 GNI Group Ltd. Business Overview
  82. 7.14.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio
  84. 7.14.5 GNI Group Ltd. Recent Developments
  85. 7.15 Diffusion Pharmaceuticals Inc.
  86. 7.15.1 Diffusion Pharmaceuticals Inc. Company Information
  87. 7.15.2 Diffusion Pharmaceuticals Inc. Business Overview
  88. 7.15.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio
  90. 7.15.5 Diffusion Pharmaceuticals Inc. Recent Developments
  91. 7.16 Cumberland Pharmaceuticals, Inc.
  92. 7.16.1 Cumberland Pharmaceuticals, Inc. Company Information
  93. 7.16.2 Cumberland Pharmaceuticals, Inc. Business Overview
  94. 7.16.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio
  96. 7.16.5 Cumberland Pharmaceuticals, Inc. Recent Developments
  97. 7.17 Cleveland BioLabs, Inc.
  98. 7.17.1 Cleveland BioLabs, Inc. Company Information
  99. 7.17.2 Cleveland BioLabs, Inc. Business Overview
  100. 7.17.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio
  102. 7.17.5 Cleveland BioLabs, Inc. Recent Developments
  103. 7.18 Chrysalis BioTherapeutics, Inc.
  104. 7.18.1 Chrysalis BioTherapeutics, Inc. Company Information
  105. 7.18.2 Chrysalis BioTherapeutics, Inc. Business Overview
  106. 7.18.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  108. 7.18.5 Chrysalis BioTherapeutics, Inc. Recent Developments
  109. 7.19 Cellphire, Inc.
  110. 7.19.1 Cellphire, Inc. Company Information
  111. 7.19.2 Cellphire, Inc. Business Overview
  112. 7.19.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio
  114. 7.19.5 Cellphire, Inc. Recent Developments
8 North America
  1. 8.1 North America Choroidal Neovascularization Drug Market Size by Type
  2. 8.1.1 North America Choroidal Neovascularization Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Choroidal Neovascularization Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Choroidal Neovascularization Drug Price by Type (2021-2032)
  5. 8.2 North America Choroidal Neovascularization Drug Market Size by Application
  6. 8.2.1 North America Choroidal Neovascularization Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Choroidal Neovascularization Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Choroidal Neovascularization Drug Price by Application (2021-2032)
  9. 8.3 North America Choroidal Neovascularization Drug Market Size by Country
  10. 8.3.1 North America Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Choroidal Neovascularization Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Choroidal Neovascularization Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Choroidal Neovascularization Drug Market Size by Type
  2. 9.1.1 Europe Choroidal Neovascularization Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Choroidal Neovascularization Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Choroidal Neovascularization Drug Price by Type (2021-2032)
  5. 9.2 Europe Choroidal Neovascularization Drug Market Size by Application
  6. 9.2.1 Europe Choroidal Neovascularization Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Choroidal Neovascularization Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Choroidal Neovascularization Drug Price by Application (2021-2032)
  9. 9.3 Europe Choroidal Neovascularization Drug Market Size by Country
  10. 9.3.1 Europe Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Choroidal Neovascularization Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Choroidal Neovascularization Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Choroidal Neovascularization Drug Market Size by Type
  2. 10.1.1 China Choroidal Neovascularization Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Choroidal Neovascularization Drug Sales by Type (2021-2032)
  4. 10.1.3 China Choroidal Neovascularization Drug Price by Type (2021-2032)
  5. 10.2 China Choroidal Neovascularization Drug Market Size by Application
  6. 10.2.1 China Choroidal Neovascularization Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Choroidal Neovascularization Drug Sales by Application (2021-2032)
  8. 10.2.3 China Choroidal Neovascularization Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Choroidal Neovascularization Drug Market Size by Type
  2. 11.1.1 Asia Choroidal Neovascularization Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Choroidal Neovascularization Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Choroidal Neovascularization Drug Price by Type (2021-2032)
  5. 11.2 Asia Choroidal Neovascularization Drug Market Size by Application
  6. 11.2.1 Asia Choroidal Neovascularization Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Choroidal Neovascularization Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Choroidal Neovascularization Drug Price by Application (2021-2032)
  9. 11.3 Asia Choroidal Neovascularization Drug Market Size by Country
  10. 11.3.1 Asia Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Choroidal Neovascularization Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Choroidal Neovascularization Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Choroidal Neovascularization Drug Market Size by Type
  2. 12.1.1 SAMEA Choroidal Neovascularization Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Choroidal Neovascularization Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Choroidal Neovascularization Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Choroidal Neovascularization Drug Market Size by Application
  6. 12.2.1 SAMEA Choroidal Neovascularization Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Choroidal Neovascularization Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Choroidal Neovascularization Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Choroidal Neovascularization Drug Market Size by Country
  10. 12.3.1 SAMEA Choroidal Neovascularization Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Choroidal Neovascularization Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Choroidal Neovascularization Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Choroidal Neovascularization Drug Value Chain Analysis
  2. 13.1.1 Choroidal Neovascularization Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Choroidal Neovascularization Drug Production Mode & Process
  6. 13.2 Choroidal Neovascularization Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Choroidal Neovascularization Drug Distributors
  9. 13.2.3 Choroidal Neovascularization Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst